Frailty Poses No Limit to HFpEF Meds

Increased frailty of patients with heart failure with preserved ejection fraction should have no bearing on whether those patients receive sacubitril/valsartan, according to results of a data analysis.

Related Keywords

Zagreb ,Grad ,Croatia ,Copenhagen ,Køavn ,Denmark ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Georgea Heckman ,Maja Cikes ,Kenneth Rockwood ,University Of Waterloo Canada ,Journal Of The American College Cardiology ,European Society Of Cardiology ,Drug Administration ,Dalhousie University In Halifax ,University Hospital Center Zagreb ,Copenhagen University Hospital ,European Society ,American College ,Valsartan Because ,Copenhagen University ,Without Increasing ,Dalhousie University ,Heart Failure ,Frailty ,Frailty Syndrome ,Elderly Concerns Of Older Adults ,Meta Analysis ,Hospitals ,Inpatient Care ,Drug Treatment Safety ,Ejection Fraction Ef ,Eft Ventricular Ejection Fraction Lvef ,Geriatrics Elder Care ,Medical Literature ,Books ,Textbooks ,Ournals ,Patient Safety ,